These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 2690681)

  • 1. Presence of Apo B48, and relative Apo CII deficiency and Apo CIII enrichment in uremic very-low density lipoproteins.
    Atger V; Beyne P; Frommherz K; Roullet JB; Drüeke T
    Ann Biol Clin (Paris); 1989; 47(8):497-501. PubMed ID: 2690681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anomalies in composition of uremic lipoproteins isolated by gradient ultracentrifugation: relative enrichment of HDL in apolipoprotein C-III at the expense of apolipoprotein A-I.
    Atger V; Duval F; Frommherz K; Drüeke T; Lacour B
    Atherosclerosis; 1988 Nov; 74(1-2):75-83. PubMed ID: 3145749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
    Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
    Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased VLDL apoprotein CII/apoprotein CIII ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment.
    Wakabayashi Y; Okubo M; Shimada H; Sato N; Koide A; Marumo F; Nakamura H
    Metabolism; 1987 Sep; 36(9):815-20. PubMed ID: 3626863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid and apolipoproteins (ApoAI, ApoB, Apo CIII, ApoE) disturbance in hemodialysis (HD) and renal transplant (Tx) patients.
    Janicki K; Solski J; Janicka L; Kimak E; Bednarek-Skublewska A; Stettner S; Molas G
    Ann Univ Mariae Curie Sklodowska Med; 2004; 59(1):459-66. PubMed ID: 16146031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
    Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
    Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.
    Baggio G; Manzato E; Gabelli C; Fellin R; Martini S; Enzi GB; Verlato F; Baiocchi MR; Sprecher DL; Kashyap ML
    J Clin Invest; 1986 Feb; 77(2):520-7. PubMed ID: 3944267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.
    Hiukka A; Fruchart-Najib J; Leinonen E; Hilden H; Fruchart JC; Taskinen MR
    Diabetologia; 2005 Jun; 48(6):1207-15. PubMed ID: 15864534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
    Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
    J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in lipoproteins induced by the remnant kidney tissue or binephrectomy in chronic uremic patients treated by hemodialysis.
    Robert D; Jeanmonod R; Favre H; Fruchart JC; Sturzenegger E; Riesen W
    Metabolism; 1989 Jun; 38(6):514-21. PubMed ID: 2498613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Apolipoprotein C-II and C-III anomalies in normolipemic and hyperlipemic patients with chronic kidney failure].
    Tornero F; García-Garzón A; Rincón B; Prieto S; Usón J; Lozano L
    Nefrologia; 2000; 20(1):47-53. PubMed ID: 10822722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Composition and distribution of lipid and apolipoprotein in plasma lipoproteins of endogenous hypertriglyceridemia].
    Zhang L; Liu B
    Hua Xi Yi Ke Da Xue Xue Bao; 1992 Jun; 23(2):117-21. PubMed ID: 1452137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia.
    Hsu HC; Lee YT; Yeh HT; Chen MF
    J Lab Clin Med; 2001 Jun; 137(6):414-21. PubMed ID: 11385362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of obesity on the metabolism of apolipoprotein B in humans.
    Egusa G; Beltz WF; Grundy SM; Howard BV
    J Clin Invest; 1985 Aug; 76(2):596-603. PubMed ID: 4031064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catabolism of very-low-density lipoproteins in subjects with broad beta disease: comparison with endogenous hypertriglyceridemia.
    Kushwaha RS; Chait A; Hazzard WR
    J Lab Clin Med; 1982 Jan; 99(1):15-24. PubMed ID: 6948063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anomalies of lipoprotein metabolism in chronic renal insufficiency].
    Lacour B; Massy ZA; Jungers P; Drueke T
    Nephrologie; 1993; 14(2):75-90. PubMed ID: 8327031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?
    Battula SB; Fitzsimons O; Moreno S; Owens D; Collins P; Johnson A; Tomkin GH
    Metabolism; 2000 Aug; 49(8):1049-54. PubMed ID: 10954025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.
    Lee SJ; Campos H; Moye LA; Sacks FM
    Arterioscler Thromb Vasc Biol; 2003 May; 23(5):853-8. PubMed ID: 12637336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein and lipid composition of plasma lipoproteins in neonates during the first month of life.
    van Biervliet JP; Rosseneu M; Bury J; Caster H; Stul MS; Lamote R
    Pediatr Res; 1986 Apr; 20(4):324-8. PubMed ID: 3085061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipids and apolipoproteins change during the progression of chronic renal failure.
    Bergesio F; Monzani G; Ciuti R; Serruto A; Benucci A; Frizzi V; Salvadori M
    Clin Nephrol; 1992 Nov; 38(5):264-70. PubMed ID: 1451339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.